Palatin Technologies Secures €5.5 Million Milestone for Retinal Disease Treatment with Boehringer Ingelheim Palatin Technologies achieves a significant milestone payment of €5.5 million in collaboration with Boehringer Ingelheim for developing treatments targeting retinal diseases.

Palatin Technologies Secures €5.5 Million Milestone for Retinal Disease Treatment with Boehringer Ingelheim #United_States #Boehringer_Ingelheim #Palatin_Technologies #Princeton #Retinal_Disease

Nanoscope Therapeutics to Showcase Vision Restoration Breakthroughs at Upcoming Eyecelerator and ARVO 2025 Events Nanoscope Therapeutics announces its participation in Eyecelerator and ARVO 2025 meetings, showcasing success of optogenetic therapies aimed at restoring vision for retinal disease patients.

Nanoscope Therapeutics to Showcase Vision Restoration Breakthroughs at Upcoming Eyecelerator and ARVO 2025 Events #United_States #Salt_Lake_City,_Utah #Nanoscope #Optogenetics #Retinal_Disease